Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ESLA

Estrella Immunopharma Inc

Last Close
Jul 26 04:00PM ET
2.21
Dollar change
+0.50
Percentage change
29.24
%
Index- P/E- EPS (ttm)-0.18 Insider Own74.94% Shs Outstand36.38M Perf Week61.31%
Market Cap80.40M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.12M Perf Month140.22%
Income-0.63M PEG- EPS next Q- Inst Own0.31% Short Float0.21% Perf Quarter112.50%
Sales0.00M P/S- EPS this Y- Inst Trans0.09% Short Ratio0.99 Perf Half Y82.64%
Book/sh0.23 P/B9.50 EPS next Y- ROA-2.28% Short Interest0.02M Perf Year-77.90%
Cash/sh0.13 P/C17.00 EPS next 5Y- ROE-2.51% 52W Range0.81 - 33.00 Perf YTD99.10%
Dividend Est.- P/FCF- EPS past 5Y- ROI-7.47% 52W High-93.30% Beta0.05
Dividend TTM- Quick Ratio62.34 Sales past 5Y- Gross Margin- 52W Low172.84% ATR (14)0.25
Dividend Ex-Date- Current Ratio62.34 EPS Y/Y TTM-44.10% Oper. Margin0.00% RSI (14)84.33 Volatility25.08% 14.84%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q51.47% Payout- Rel Volume204.37 Prev Close1.71
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume19.30K Price2.21
SMA2068.15% SMA50101.04% SMA20085.74% Trades Volume3,943,852 Change29.24%
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.